A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer

References

Page 1

	Year	Citations
New Guidelines to Evaluate the Response to Treatment in Solid Tumors Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, JNCI Journal of the National Cancer Institute World Health OrganizationSolid TumorsCancer ManagementMetronomic ChemotherapyResponse Assessment	2000	15.7K
Toxicity and response criteria of the Eastern Cooperative Oncology Group Martin M. Oken, Richard H. Creech, Douglass C. Tormey, American Journal of Clinical Oncology Health SciencesMedicineCancer ManagementClinical EndpointPharmacology	1982	11.4K
Optimal two-stage designs for phase II clinical trials Richard Simon Controlled Clinical Trials Clinical Trial ManagementClinical TrialsRandomized Controlled TrialBiostatisticsDrug Trial	1989	3.6K
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Christopher G. Willett, Yves Boucher, Emmanuelle di Tomaso, Nature Medicine AngiogenesisMedicineHuman Rectal CancerImmunologyPathology	2004	1.9K
Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth David Lyden, Koichi Hattori, Sérgio Dias, Nature Medicine AngiogenesisMedicineStem Cell MobilizationHematopoietic Precursor CellsStem Cell Research	2001	1.9K
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan Alan N. Gordon, John Fleagle, David Guthrie, Journal of Clinical Oncology	2001	1.2K
Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study Robert A. Burger, Michael W. Sill, Bradley J. Monk, Journal of Clinical Oncology	2007	878
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. Maurie Markman, Robert Rothman, Thomas B. Hakes, Journal of Clinical Oncology Surgical OncologyOverall Response RatesCisplatin ProgramsMedicineCancer Management	1991	851
Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer Stephen A. Cannistra, Ursula A. Matulonis, Richard T. Penson, Journal of Clinical Oncology	2007	754
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. W ten Bokkel Huinink, Martin Gore, J Carmichael, Journal of Clinical Oncology	1997	681

Page 1